INVITAE CORP (NVTA)
US46185L1035 - Common Stock
We assign a fundamental rating of 2 out of 10 to NVTA. NVTA was compared to 117 industry peers in the Health Care Providers & Services industry. NVTA has a bad profitability rating. Also its financial health evaluation is rather negative. NVTA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NVTA had negative earnings in the past year.
In the past year NVTA has reported a negative cash flow from operations.
In the past 5 years NVTA always reported negative net income.
NVTA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NVTA has a Return On Assets of -269.22%. This is amonst the worse of the industry: NVTA underperforms 96.49% of its industry peers.
NVTA's Return On Invested Capital of 381.98% is amongst the best of the industry. NVTA outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -269.22% | ||
| ROE | N/A | ||
| ROIC | 381.98% |
ROA(3y)-61.41%
ROA(5y)-52.18%
ROE(3y)-1031.52%
ROE(5y)-647.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVTA has a Operating Margin of 378.20%. This is amongst the best in the industry. NVTA outperforms 100.00% of its industry peers.
NVTA has a Gross Margin (27.14%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NVTA has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 378.2% | ||
| PM (TTM) | N/A | ||
| GM | 27.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.59%
GM growth 5Y-3.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NVTA is creating value.
NVTA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVTA has more shares outstanding
The debt/assets ratio for NVTA is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.51, we must say that NVTA is in the distress zone and has some risk of bankruptcy.
NVTA has a Altman-Z score of -3.51. This is amonst the worse of the industry: NVTA underperforms 86.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.51 |
ROIC/WACC172.06
WACC2.22%
2.3 Liquidity
A Current Ratio of 2.39 indicates that NVTA has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.39, NVTA is doing good in the industry, outperforming 79.82% of the companies in the same industry.
A Quick Ratio of 2.25 indicates that NVTA has no problem at all paying its short term obligations.
The Quick ratio of NVTA (2.25) is better than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
NVTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.74%, which is quite impressive.
NVTA shows a decrease in Revenue. In the last year, the revenue decreased by -7.37%.
Measured over the past years, NVTA shows a very strong growth in Revenue. The Revenue has been growing by 49.91% on average per year.
EPS 1Y (TTM)58.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q76.19%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y33.54%
Revenue growth 5Y49.91%
Revenue growth Q2Q-9.21%
3.2 Future
The Earnings Per Share is expected to grow by 12.71% on average over the next years. This is quite good.
Based on estimates for the next years, NVTA will show a small growth in Revenue. The Revenue will grow by 3.73% on average per year.
EPS Next Y53.25%
EPS Next 2Y26.21%
EPS Next 3Y18.34%
EPS Next 5Y12.71%
Revenue Next Year-6.03%
Revenue Next 2Y0.81%
Revenue Next 3Y3.75%
Revenue Next 5Y3.73%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NVTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVTA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NVTA is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.53 |
4.3 Compensation for Growth
NVTA's earnings are expected to grow with 18.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.21%
EPS Next 3Y18.34%
5. Dividend
5.1 Amount
No dividends for NVTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INVITAE CORP
NYSE:NVTA (2/5/2024, 6:40:05 PM)
0.0891
-0.3 (-77.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.53M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -269.22% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 378.2% | ||
| PM (TTM) | N/A | ||
| GM | 27.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y53.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y33.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y